FTH1 and glioblastoma: [153] developed a brain-targeted nanoplatform (HFn-Cu-REGO NPs), incorporating human H-ferritin (HFn), regorafenib, and Cu2+, enabling site-specific delivery and modulation of autophagy and cuproptosis against glioblastoma multiforme (GBM) (Fig. S3A).